Scientific Sessions 2024  /  Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations  /  Discussant: OLE & HELIOS-B
Logo

American Heart Association

  2
  0

Final ID:

Discussant: OLE & HELIOS-B

  • Grogan, Martha  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Kittleson, Michelle  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Nair, Ajith  ( Baylor College of Medicine , Houston , Texas , United States )
  • Grodin, Justin  ( UT SOUTHWESTERN , Dallas , Texas , United States )
  • Ambardekar, Amrut  ( , Aurora , Colorado , United States )
    • Author Disclosures:
    Martha Grogan: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alnylam:Active (exists now) ; Advisor:NovoNordisk:Active (exists now) ; Advisor:AztraZeneca:Active (exists now) ; Consultant:Janssen:Active (exists now) ; Research Funding (PI or named investigator):Janssen:Past (completed) ; Research Funding (PI or named investigator):NovoNordisk:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Past (completed) ; Research Funding (PI or named investigator):Eidos:Active (exists now) | Michelle Kittleson: DO NOT have relevant financial relationships | Ajith Nair: DO have relevant financial relationships ; Speaker:Janssen:Active (exists now) ; Consultant:Abbott:Past (completed) ; Advisor:Gossamer Bio:Past (completed) ; Speaker:Impulse Dynamics:Past (completed) | Justin Grodin: DO have relevant financial relationships ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Consultant:Sarepta:Past (completed) ; Consultant:Tenax:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Alexion:Active (exists now) ; Consultant:Alnylam:Past (completed) ; Consultant:Astra-Zeneca:Active (exists now) ; Consultant:Pfizer:Active (exists now) ; Research Funding (PI or named investigator):Eidos/BridgeBio:Past (completed) | Amrut Ambardekar: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Amyloid, Hypertrophic, and Danon Cardiomyopathies: Targeted Therapies and Specific Populations

Monday, 11/18/2024 , 09:45AM - 11:00AM

Featured Science

More abstracts on this topic:
The prevalence of transthyretin cardiac amyloidosis in older Black and Hispanic individuals with heart failure: The Screening for Cardiac Amyloidosis with Nuclear imaging in Minority Populations Study

Ruberg Frederick, Blaner William, Deluca Albert, Johnson Lynne, Kinkhabwala Mona, Leb Jay, Mintz Akiva, Lavalley Michael, Einstein Andrew, Cohn Elizabeth, Kelly Jeffery, Teruya Sergio, Miller Edward, Maurer Mathew, Helmke Stephen, Fine Denise, Kurian Damian, Raiszadeh Farbod, Connors Lawreen, Prokaeva Tatiana, Pandey Shivda

Discussant: Danon Disease Phase 1 RP-A501

Gillmore Julian, Taylor Matthew, Adler Eric

More abstracts from these authors:
5 Key Lessons learned about Cardiac Amyloidosis in the last 10 years and what remains to be learned. 10 minutes

Maurer Mathew, Ambardekar Amrut

The Final Battle: Advanced Heart Failure and AF - HF Top 5 Take Aways

Ambardekar Amrut, Kittleson Michelle

You have to be authorized to contact abstract author. Please, Login
Not Available